References
- MILLER KD, NOGUEIRA L, DEVASIA T, MARIOTTO AB, YABROFF KR, JEMAL A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022 Sep;72(5):409–436.
- MANGONE L, MANCUSO P, TARANTINI L, LAROCCA M, BISCEGLIA I, DAMATO A, et al. A Population-Based Study of Cardiovascular Disease Mortality in Italian Cancer Patients. Cancers (Basel). 2021 Nov 24;13(23):5903.
- SCHINDLER M, SPYCHER BD, AMMANN RA, ANSARI M, MICHEL G, KUEHNI CE; SWISS PAEDIATRIC ONCOLOGY GROUP (SPOG). Cause-specific long-term mortality in survivors of childhood cancer in Switzerland: A population-based study. Int J Cancer. 2016 Jul 15;139(2):322–33.
- STRONGMAN H, GADD S, MATTHEWS A, MANSFIELD KE, STANWAY S, LYON AR, et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet. 2019 Sep 21;394(10203):1041–1054.
- PATERSON DI, WIEBE N, CHEUNG WY, MACKEY JR, PITUSKIN E, REIMAN A, et al. Incident Cardiovascular Disease Among Adults With Cancer: A Population-Based Cohort Study. JACC CardioOncol. 2022 Mar 15;4(1):85–94.
- CARDINALE D, COLOMBO A, BACCHIANI G, TEDESCHI I, MERONI CA, VEGLIA F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015 Jun 2;131(22):1981–8.
- SMITH LA, CORNELIUS VR, PLUMMER CJ, LEVITT G, VERRILL M, CANNEY P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010 Jun 29;10:337.
- SAWAYA H, SEBAG IA, PLANA JC, JANUZZI JL, KY B, COHEN V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011 May 1;107(9):1375–80.
- LYON AR, LÓPEZ-FERNÁNDEZ T, COUCH LS, ASTEGGIANO R, AZNAR MC, BERGLER-KLEIN J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov 1;43(41):4229–4361.
- ALEXANDRE J, CAUTELA J, EDERHY S, DAMAJ GL, SALEM JE, BARLESI F, et al. Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. J Am Heart Assoc. 2020 Sep 15;9(18):e018403.
- ANANTHAN K, LYON AR. The Role of Biomarkers in Cardio-Oncology. J Cardiovasc Transl Res. 2020 Jun;13(3):431–450.
- LANCELLOTTI P, SUTER TM, LÓPEZ-FERNÁNDEZ T, GALDERISI M, LYON AR, VAN DER MEER P, et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J. 2019 Jun 7;40(22):1756–1763.
- FLORIDO R, DAYA NR, NDUMELE CE, KOTON S, RUSSELL SD, PRIZMENT A, et al. Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study. J Am Coll Cardiol. 2022 Jul 5;80(1):22–32.
- KORIC A, CHANG CP, MARK B, ROWE K, SNYDER J, DODSON M, et al. Cardiovascular disease risk in long-term breast cancer survivors: A population-based cohort study. Cancer. 2022 Jul 15;128(14):2826–2835.
- PIEPOLI MF, HOES AW, AGEWALL S, ALBUS C, BROTONS C, CATAPANO AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Prev Cardiol. 2016 Jul;23(11):NP1–NP96.
- CARLSON LE, WATT GP, TONOREZOS ES, CHOW EJ, YU AF, WOODS M, et al. Coronary Artery Disease in Young Women After Radiation Therapy for Breast Cancer: The WECARE Study. JACC CardioOncol. 2021 Sep 21;3(3):381–392.
- RAGHUNATHAN D, KHILJI MI, HASSAN SA, YUSUF SW. Radiation-Induced Cardiovascular Disease. Curr Atheroscler Rep. 2017 May;19(5):22.
- LIU JE, BARAC A, THAVENDIRANATHAN P, SCHERRER-CROSBIE M. Strain Imaging in Cardio-Oncology. JACC CardioOncol. 2020 Dec 15;2(5):677–689.
- BRADY B, KING G, MURPHY RT, WALSH D. Myocardial strain: a clinical review. Ir J Med Sci. 2022 Nov 16:1–8.
- LIU JE, BARAC A, THAVENDIRANATHAN P, SCHERRER-CROSBIE M. Strain Imaging in Cardio-Oncology. JACC CardioOncol. 2020 Dec 15;2(5):677–689.
- MICHEL L, MINCU RI, MAHABADI AA, SETTELMEIER S, AL-RASHID F, RASSAF T, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020 Feb;22(2):350–361.
- BRACUN V, ABOUMSALLEM JP, VAN DER MEER P, DE BOER RA. Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues. Curr Oncol Rep. 2020 Jun 9;22(7):67.
- CARDINALE D, COLOMBO A, TORRISI R, SANDRI MT, CIVELLI M, SALVATICI M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010 Sep 1;28(25):3910–6.
- GOLDENBERG I, MOSS AJ, ZAREBA W. QT interval: how to measure it and what is "normal". J Cardiovasc Electrophysiol. 2006 Mar;17(3):333–6.
- POSTEMA PG, WILDE AA. The measurement of the QT interval. Curr Cardiol Rev. 2014 Aug;10(3):287–94.
- PORTA-SÁNCHEZ A, GILBERT C, SPEARS D, AMIR E, CHAN J, NANTHAKUMAR K, et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc. 2017 Dec 7;6(12):e007724.
- ZAMORANO JL, GOTTFRIDSSON C, ASTEGGIANO R, ATAR D, BADIMON L, BAX JJ, et al. The cancer patient and cardiology. Eur J Heart Fail. 2020 Dec;22(12):2290–2309.
- BABIKER HM, MCBRIDE A, NEWTON M, BOEHMER LM, DRUCKER AG, GOWAN M, et al. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Crit Rev Oncol Hematol. 2018 Jun;126:186–200.
- PANTAZI D, TSELEPIS AD. Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms. Thromb Res. 2022 May;213 Suppl 1:S95–S102.
- MABUDIAN L, JORDAN JH, BOTTINOR W, HUNDLEY WG. Cardiac MRI assessment of anthracycline-induced cardiotoxicity. Front Cardiovasc Med. 2022 Sep 27;9:903719.
- SIMEK S, LUE B, RAO A, RAVIPATI G, VALLABHANENI S, ZHANG K, et al. Gender Differences in Diagnosis, Prevention, and Treatment of Cardiotoxicity in Cardio-Oncology. J Clin Med. 2022 Sep 1;11(17):5167.
- CEHIC DA, SVERDLOV AL, KOCZWARA B, EMERY J, NGO DTM, THORNTON-BENKO E. The Importance of Primary Care in Cardio-Oncology. Curr Treat Options Oncol. 2021 Oct 21;22(12):107.
- KOUTSOUKIS A, NTALIANIS A, REPASOS E, KASTRITIS E, DIMOPOULOS MA, PARASKEVAIDIS I. Cardio-oncology: A Focus on Cardiotoxicity. Eur Cardiol. 2018 Aug;13(1):64–69.
- KAAKEH Y, OVERHOLSER BR, LOPSHIRE JC, TISDALE JE. Drug-induced atrial fibrillation. Drugs 2012; 72 (12):617–1630.
- RAY JC, CHO P, DRAGON M, GRAHAM CG. A Case of 5-Fluorouracil-Induced Cardiac Arrest. J Emerg Med. 2016 Jan;50(1):e1–6.
- JOHNSON DB, BALKO JM, COMPTON ML, CHALKIAS S, GORHAM J, XU Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749–1755.
- MOSLEHI JJ, SALEM JE, SOSMAN JA, LEBRUN-VIGNES B, JOHNSON DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018;391:933.
- SALEM JE, ALLENBACH Y, VOZY A, BRECHOT N, JOHNSON DB, MOSLEHI JJ, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med 2019;380:2377–2379.
- BROWN SA. Preventive Cardio-Oncology: The Time Has Come. Front Cardiovasc Med. 2020 Jan 10;6:187.
- GANATRA S, CHATUR S, NOHRIA A. How to Diagnose and Manage Radiation Cardiotoxicity. JACC CardioOncol. 2020 Nov 17;2(4):655–660.
- LANCELLOTTI P, SUTER TM, LÓPEZ-FERNÁNDEZ T, GALDERISI M, LYON AR, VAN DER MEER P, et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J. 2019 Jun 7;40(22):1756–1763.